粪便样本中microRNA特征谱用于结直肠癌检测的鉴定与验证
该研究通过四阶段设计,从124例新鲜配对结直肠肿瘤与非肿瘤组织中发现差异表达的miRNA,并在粪便样本中进行技术验证和临床验证。最终确认MIR421、MIR130b-3p和MIR27a-3p在晚期肿瘤患者粪便中上调,联合粪便血红蛋白检测结直肠癌的AUC达0.93,显著优于单用粪便血红蛋白(AUC 0.67)。
要点
- 粪便MIR421、MIR27a-3p联合血红蛋白检测结直肠癌AUC为0.93,优于单用血红蛋白(AUC 0.67)。
- 在结直肠癌和晚期腺瘤组织中分别有200和324个miRNA显著失调,其中7个和5个在粪便中也失调。
- 粪便miRNA检测有望作为无创筛查手段补充现有粪便免疫化学检测。
核心结论
- 粪便中2种miRNA联合血红蛋白可较单用粪便血红蛋白更准确识别晚期腺瘤或结直肠癌患者。
研究设计与样本
- 研究分四阶段:发现阶段对124例新鲜配对结直肠肿瘤与非肿瘤样本(30例CRC,32例AA)进行全基因组miRNA表达谱分析。
- 技术验证阶段用逆转录聚合酶链反应在39例发现阶段患者子集的粪便样本和39例无结直肠肿瘤对照中定量差异miRNA。
- 临床验证阶段在767例粪便免疫化学检测阳性的独立粪便样本中用定量逆转录聚合酶链反应检测最显著上调的miRNA。
- 最后基于miRNA谱建立模型,以结肠镜检查结果为参考标准识别晚期肿瘤(CRC或AA)。
主要发现
- 在CRC和AA组织中分别有200和324个miRNA显著失调,其中7个和5个在粪便中也失调(技术验证)。
- MIR421、MIR130b-3p和MIR27a-3p在晚期肿瘤患者粪便样本中确认上调。
- 模型中粪便MIR421、MIR27a-3p和血红蛋白联合检测CRC的AUC为0.93,单用粪便血红蛋白浓度AUC为0.67。
临床怎么用
- 粪便miRNA检测可能作为现有粪便检测的补充,用于结直肠癌或晚期腺瘤的无创筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Screening for colorectal cancer (CRC) is effective in the population at average risk. The most extended strategy in organized programs involves the fecal immunochemical test, which is limited by low sensitivity for the detection of advanced adenomas (AAs). We aimed to identify microRNA (miRNA) signatures in fecal samples that identify patients with AAs or CRC and might be used in noninvasive screening. METHODS: Our study comprised 4 stages. In the discovery phase, we performed genome-wide miRNA expression profiling of 124 fresh, paired colorectal tumor and nontumor samples (30 CRC; 32 AAs) from patients in Spain. In the technical validation stage, miRNAs with altered expression levels in tumor vs nontumor tissues were quantified by reverse-transcription polymerase chain reaction in fecal samples from a subset of patients included in the discovery phase (n = 39) and individuals without colorectal neoplasms (controls, n = 39). In the clinical validation stage, the miRNAs found to be most significantly up-regulated by quantitative reverse transcription polymerase chain reaction analysis were measured in an independent set of fecal samples (n = 767) from patients with positive results from fecal immunochemical tests in a CRC screening program. Finally, we developed a model to identify patients with advanced neoplasms (CRCs or AAs) based on their miRNA profiles, using findings from colonoscopy as the reference standard. RESULTS: Among 200 and 324 miRNAs significantly deregulated in CRC and AA tissues, respectively, 7 and 5 of these miRNAs were also found to be deregulated in feces (technical validation). Of them, MIR421, MIR130b-3p, and MIR27a-3p were confirmed to be upregulated in fecal samples from patients with advanced neoplasms. In our model, the combination of fecal level of MIR421, MIR27a-3p, and hemoglobin identified patients with CRC with an area under the curve (AUC) of 0.93, compared with an AUC of 0.67 for fecal hemoglobin concentration alone. CONCLUSIONS: We found that increased levels of 2 miRNAs and hemoglobin in feces can identify patients with AAs or CRC more accurately than fecal hemoglobin concentration alone. Assays for these miRNAs might be added to fecal tests for the detection of CRC or AAs.
引用
- Duran-Sanchon S, Moreno L, Augé JM, et al. Identification and Validation of MicroRNA Profiles in Fecal Samples for Detection of Colorectal Cancer. Gastroenterology. 2019. PMID: 31622624. doi:10.1053/j.gastro.2019.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。